Beta-blocker therapy is not associated with symptoms of depression and anxiety in patients receiving an implantable cardioverterdefibrillator

Europace

Volumn 14, Issue 1, 2012, Pages 74-80

  Hoogwegt, Madelein T ^a   Kupper, Nina ^a   Theuns, Dominic A M J ^b   Jordaens, Luc ^b   Pedersen, Susanne S ^a,b  

^a TILBURG UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anxiety; Beta blockers; Depression; Implantable cardioverterdefibrillator

Indexed keywords

AMIODARONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT; PSYCHOTROPIC AGENT;

ADULT; ANXIETY; ARTICLE; CARDIOVERSION; DEFIBRILLATOR; DEPRESSION; DISTRESS SYNDROME; FEMALE; HEART DISEASE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SYMPTOM; UNIVARIATE ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANXIETY; DEFIBRILLATORS, IMPLANTABLE; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84055184326     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur295     Document Type: Article

References (50)

1. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-37. (Pubitemid 40110811)
2. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337:1576-83.
3. Pedersen SS, Theuns DAMJ, Muskens-Heemskerk A, Erdman RA, Jordaens L. Type-D personality but not implantable cardioverter-defibrillator indication is associated with impaired health-related quality of life 3 months post-implantation. Europace 2007;9:675-80. (Pubitemid 47263803)
4. Sears SF, Conti JB. Quality of life and psychological functioning of ICD patients. Heart 2002;87:488-93. (Pubitemid 34454597)
5. Godemann F, Butter C, Lampe F, Linden M, Werner S, Behrens S. Determinants of the quality of life (QoL) in patients with an implantable cardioverter/defibrillator (ICD). Qual Life Res 2004;13:411-6. (Pubitemid 38392269)
6. Ladwig K-H, Baumert J, Marten-Mittag B, Kolb C, Zrenner B, Schmitt C. Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter- defibrillators: Results from the prospective living with an implanted cardioverter-defibrillator study. Arch Gen Psychiatry 2008;65:1324-30.
7. Versteeg H, Theuns DAMJ, Erdman RAM, Jordaens L, Pedersen SS. Posttraumatic stress in implantable cardioverter defibrillator patients: The role of preimplantation distress and shocks. Int J Cardiol 2011;146:438-9.
8. Ermis C, Zadeii G, Zhu AX, Fabian W, Collins J, Lurie KG et al. Improved survival of cardiac transplantation candidates with implantable cardioverter defibrillator therapy. J Cardiovasc Electrophysiol 2003;14:578-83. (Pubitemid 36724381)
9. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999;26: 1730-37. (Pubitemid 29290470)
10. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
11. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344: 1651-8. (Pubitemid 32479962)
12. Di Lenarda A, Sabbadini G, Salvatore L, Sinagra G, Mestroni L, Pinamonti B et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999; 33:1926-34.
13. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: A critical review of the evidence. J Am Coll Cardiol 2007;50:563-72. (Pubitemid 47202065)
14. van Melle JP, Verbeek DEP, van den Berg MP, Ormel J, van der Linde MR, de Jonge P. Beta-blockers and depression after myocardial infarction: A multicenter prospective study. J Am Coll Cardiol 2006;48:2209-14. (Pubitemid 44855428)
15. Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed beta-blockers. JAMA 1986;255:357-60. (Pubitemid 16146697)
16. Cremona-Barbaro A. Propranolol and depression. Lancet 1983;321:185.
17. Thiessen BQ, Wallace SM, Blackburn JL, Wilson TQ, Bergman U. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch Intern Med 1990;150:2286-90. (Pubitemid 20365234)
18. Waal HJ. Propranolol-induced depression. Br Med J 1967;2:50.
19. Bright RA, Everitt DE. Beta-blockers and depression. Evidence against an association. JAMA 1992;267:1783-87.
20. Carney RM, Rich MW, tevelde A, Saini J, Clark K, Freedland KE. Prevalence of major depressive disorder in patients receiving beta-blocker therapy versus other medications. Am J Med 1987;83:223-6.
21. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. b-Blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288:351-7. (Pubitemid 34761614)
22. Schleifer SJ, Slater WR, Macari-Hinson MM, Coyle DA, Kahn M, Zucker HD et al. Digitalis and beta-blocking agents: Effects on depression following myocardial infarction. Am Heart J 1991;121:1397-402.
23. Luijendijk HJ, van den Berg JF, Hofman A, Tiemeier H, Stricker BH. b-blockers and the risk of incident depression in the elderly. J Clin Psychopharmacol 2011;31: 45-50.
24. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344: 1659-67.
25. Baxter AJ, Spensley A, Hildreth A, Karimova G, O'Connell JE, Gray CS. b Blockers in older persons with heart failure: Tolerability and impact on quality of life. Heart 2002;88:611-4. (Pubitemid 35418076)
26. Bulpitt CJ, Connor M, Schulte M, Fletcher AE. Bisoprolol and nifedipine retard in elderly hypertensive patients: Effect on quality of life. J Hum Hypertens 2000;14: 205-12. (Pubitemid 30153635)
27. Fu A, Li X, Zhao B. Role of beta1-adrenoceptor in the basolateral amygdala of rats with anxiety-like behavior. Brain Res 2008;1211:85-92.
28. Swartz CM. Betaxolol in anxiety disorders. Ann Clin Psychiatry 1998;10:9-14. (Pubitemid 28258681)
29. College voor Zorgverzekeringen (CVZ). b-receptorblokkerende sympathiolytica [College of health care insurances. b-receptor blocking sympathiolytics]. In: Sitsen JMA (ed). Farmacotherapeutisch Kompas 2010. [Pharmacotherapeutic Reference Book]. Utrecht: Roto Smeets Utrecht 2010. p.323-38.
30. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: An updated literature review. J Psychosom Res 2002;52:69-77. (Pubitemid 34192886)
31. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-70. (Pubitemid 13098606)
32. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 1997;27:363-70. (Pubitemid 27139969)
33. Pedersen SS, van Domburg RT, Theuns DAMJ, Jordaens L, Erdman RAM. Concerns about the implantable cardioverter defibrillator: A determinant of anxiety and depressive symptoms independent of experienced shocks. Am Heart J 2005;149:664-9.
34. Pedersen SS, van den Broek KC, Erdman RAM, Jordaens L, Theuns DAMJ. Preimplantation implantable cardioverter defibrillator concerns and Type D personality increase the risk of mortality in patients with an implantable cardioverter defibrillator. Europace 2010;12:1446-52.
35. Frizelle DJ, Lewin B, Kaye G, Moniz-Cook ED. Development of a measure of the concerns held by people with implanted cardioverter defibrillators: The ICDC. Br J Health Psychol 2006;11:293-301. (Pubitemid 43799743)
36. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: Implications for the assessment of investigational therapy. J Am Coll Cardiol 2000; 36:1303-9.
37. Johansen JB, Pedersen SS, Spindler H, Andersen K, Nielsen JC, Mortensen PT. Symptomatic heart failure is the most important clinical correlate of impaired quality of life, anxiety, and depression in implantable cardioverter-defibrillator patients: A single-centre, cross-sectional study in 610 patients. Europace 2008; 10:545-51. (Pubitemid 351775296)
38. Pedersen SS, Van Den Berg M, Erdman RAM, Van Son J, Jordaens LUC, Theuns DAMJ. Increased anxiety in partners of patients with a cardioverter- defibrillator: The role of indication for ICD therapy, shocks, and personality. Pacing Clin Electrophysiol 2009;32:184-92.
39. Nouwen A, Winkley K, Twisk J, Lloyd C, Peyrot M, Ismail K et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: A systematic review and meta-analysis. Diabetologia 2010;53:2480-6.
40. Babyak MA. What you see may not be what you get: A brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med 2004;66:411-21. (Pubitemid 38668414)
41. Bremner JD, Krystal JH, Southwick SM, Charney DS. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse 1996;23:39-51. (Pubitemid 26138646)
42. LeDoux JE. The Emotional Brain. Malden, MA, USA: Blackwell Publishers; 1998.
43. Lampert R, Shusterman V, Burg M, McPherson C, Batsford W, Goldberg A et al. Anger-induced T-wave alternans predicts future ventricular arrhythmias in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol 2009;53: 774-8.
44. Verma A, Wulffhart Z, Lakkireddy D, Khaykin Y, Kaplan A, Sarak B et al. Incidence of left ventricular function improvement after primary prevention ICD implantation for non-ischaemic dilated cardiomyopathy: A multicenter experience. Heart 2010;96:510-5.
45. Rabiner EA, Gunn RN, Castro ME, Sargent PA, Cowen PJ, Koepp MJ et al. Betablocker binding to human 5-HT(1A) receptors in vivo and in vitro: Implications for antidepressant therapy. Neuropsychopharmacology 2000;23:285-93. (Pubitemid 30609662)
46. Patten SB, Barbui C. Drug-induced depression: A systematic review to inform clinical practice. Psychother Psychosom 2004;73:207-15. (Pubitemid 38822722)
47. Suzuki T, Shiga T, Kuwahara K, Kobayashi S, Suzuki S, Nishimura K et al. Prevalence and persistence of depression in patients with implantable cardioverter defibrillator: A 2-year longitudinal study. Pacing Clin Electrophysiol 2010;33: 1455-61.
48. Verbeek DEP, Van Riezen J, De Boer RA, Van Melle JP, De Jonge P. A review on the putative association between beta-blockers and depression. Heart Fail Clin 2011;7:89-99.
49. Hevey D, McGee HM, Horgan J. Responsiveness of health-related quality of life outcome measures in cardiac rehabilitation: Comparison of cardiac rehabilitation outcome measures. J Consult Clin Psychol 2004;72:1175-80. (Pubitemid 39658551)
50. van den Broek KC, Nyklícek I, van der Voort PH, Alings M, Meijer A, Denollet J. Risk of ventricular arrhythmia after implantable defibrillator treatment in anxious type D patients. J Am Coll Cardiol 2009;54:531-7.